From the research that I have access to, this deal if it happens, should expand earnings forecasts because it was recognized as a possibility, but not factored into most forecasts.This should bode well for price appreciation through positive earnings surprises and possible PE multiple expansion as DOSE becomes the recognized industry leader in the institutional pharmacy industry.Barring unforseen events, $20 to $24 per share over the next 12 months is very feasable.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Ma